ThermoGenesis and UC Davis Stem Cell Program Collaborate to Develop Stem Cell Treatments
Complete the form below to unlock access to ALL audio articles.
ThermoGenesis Corp. and the Stem Cell Program at the University of California, Davis (SCP) have announced a collaborative research agreement to develop stem cell therapies based upon ThermoGenesis' AutoXpress™ (AXP), BioArchive® and CryoSeal® Fibrin Sealant (FS) blood processing systems.
"Through this collaboration, we and our research collaborators at SCP will be investigating the cell populations and fibrin gel carriers isolated from bone marrow and cord blood using our blood processing systems. The focus will be on stem cell treatments for peripheral artery disease, myocardial infarction and dermal wounds,” said Philip Coelho, ThermoGenesis' Chairman and Chief Executive Officer.
Mr. Coelho continued, “Our systems are well positioned to competitively provide the stem cells that the physicians need to treat these large patient population diseases. It is exciting to be working with Dr. Jan Nolta and Gerhard Bauer who are internationally recognized stem cell experts.”
Under the terms of the agreement, ThermoGenesis will supply SCP with an AXP Platform, one BioArchive and one CryoSeal FS System for use in their translational cell therapy research, which will focus on sourcing the stem cells from the patient's own bone marrow or umbilical cord blood. ThermoGenesis will have first option to negotiate a license to the resulting intellectual property.
"UC Davis is committed to playing a leading role in unlocking the potential of non-controversial adult stem cells and advancing these cell therapies into clinical practice as treatments for numerous life-threatening diseases," said Dr. Jan A. Nolta, Stem Cell Program director at UC Davis School of Medicine.
"We look forward to researching the stem cells isolated by ThermoGenesis AXP technology. Their technologies for stem cell isolation and stem cell storage may be important for scaling up stem cell therapies to meet the demands for wide acceptance and success in clinical practice," Nolta added.